Philogen Announces Publication of Best-in-Class FAP-Targeting Small Molecule Ligand (OncoFAP) in PNAS

Philogen S.p.A., a listed clinical-stage biotechnology company focused on the development of innovative medicines based on tumor targeting antibodies and small molecule ligands, is pleased to announce a publication describing the development and the in vivo characterization of OncoFAP, a best-in-class FAP-targeting small molecule for applications in cancer and inflammation. The paper entitled “An Ultra-High … Read more

Porex Life Sciences Institute Establishes Innovation Center to Address Market Demand for New Life Sciences Technologies

Filtration Group—a global leader producing best-in-class filtration solutions to make the world safer, healthier and more productive—today announced the launch of the Porex Life Sciences Institute, a new business unit dedicated to the advancement of life science technologies. The Porex Life Sciences Institute is located in close proximity to Atlanta’s med-tech innovation corridor. The Institute will … Read more

Philogen Announces Participation to the 10th World Congress of Melanoma

Philogen S.p.A., a listed clinical-stage biotechnology company focused on the development of innovative medicines based on tumor-targeting antibodies and small molecule ligands, is pleased to announce its participation in the 10th World Congress of Melanoma, a virtual event taking place from April 15 to 17, 2021. Philogen, which is one of the sponsors of this congress, will … Read more

Philogen Announces Publication of the Construction and Application of an Innovative DNA-Encoded Chemical Library in Nature Chemistry

Philogen S.p.A., a listed clinical-stage biotechnology company focused on the development of innovative medicines based on tumor-targeting antibodies and small molecule ligands, is pleased to announce a publication describing the construction of a DNA-encoded chemical library (DEL) that was successfully screened against multiple protein targets, yielding potent and selective small molecule binders against disease-relevant antigens. … Read more

Medication Adherence Market Expanding Due to Specialized Market Entrants

Medication doesn’t help much if you don’t take it. Medication adherence refers to patients taking the medication prescribed by their healthcare providers at the correct dosage and timing. Medication nonadherence is an important public health concern, affecting health outcomes and overall healthcare costs for virtually all chronic diseases. Half of all patients do not take … Read more

Remiges Ventures Closes Second Fund With $95 Million; Launches RDiscovery Incubator

Remiges Ventures, a US-based cross-border venture capital firm with offices in Seattle, WA and Tokyo, Japan, announced today the final closing of its second fund, Remiges BioPharma Fund II raising a total of $95 million by welcoming new and returning investors, including Taiho Pharmaceutical Co., Ltd. (Tokyo, Japan), Sumitomo Dainippon Pharma Co., Ltd. (Osaka, Japan), … Read more

GB Sciences Joins Newswire’s Guided Tour Program to Showcase Its Capabilities as a Phytomedicine Company

GB Sciences, a phytomedicine research and biopharmaceutical drug development company, recently joined Newswire’s Earned Media Advantage Guided Tour program. With a goal to create patented formulations for safe, standardized, plant-inspired therapies that target a variety of medical conditions, GB Sciences is leaning on Newswire’s team of public relations (PR) experts to build recognition for their … Read more

Enterin Announces Appointment of Donald Munoz to Its Board of Directors

Enterin, Inc., a clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative diseases, announces the appointment of Donald Munoz to its Board of Directors. “We are thrilled to welcome Don to Enterin’s Board,” said David McCullough, Enterin’s Chief Executive Officer. “He brings significant biotechnology industry expertise and tremendous financial experience given his roles as a public-company CFO and … Read more

Nemysis Ltd Establishes a New Subsidiary in the U.S.

Nemysis Limited, the Dublin based pharmaceutical and healthcare Company, focused on Iron Deficiency/Anemia and Gluten Sensitivity, announced today the establishment and commencement of operations of Enteralia Bioscience LLC, the Company’s new pharmaceutical R&D subsidiary in The United States of America. The opening of this subsidiary is a first step in the company’s strategy to expand … Read more